Antiviral activity of the interferon α family: Biological and pharmacological aspects of the treatment of chronic hepatitis C

Expert Opinion on Biological Therapy

Volumn 13, Issue 5, 2013, Pages 693-711

  Scagnolari, Carolina ^a   Antonelli, Guido ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Hepatitis C virus; Interferon ; Interferon ; Interferon stimulated genes; Interleukin 28B; MicroRNA; Neutralizing antibody

Indexed keywords

ALBINTERFERON ALPHA2B; ALPHA INTERFERON; BELEROFON; BETA1A INTERFERON; CINNOVEX; CONSENSUS INTERFERON; INTERFERON; INTERFERON BETA SERINE; JOULFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RETARD; UNCLASSIFIED DRUG; ZALBIN; ZIFERON;

ANTIPROLIFERATIVE ACTIVITY; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CLEARANCE; CONTROLLED RELEASE FORMULATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STABILITY; DRUG TOLERABILITY; HEPATITIS C; HUMAN; IMMUNOGENICITY; META ANALYSIS (TOPIC); NONHUMAN; REVIEW; SYSTEMATIC REVIEW (TOPIC); TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; RECEPTORS, CELL SURFACE; TREATMENT OUTCOME;

HEPATITIS C VIRUS;

EID: 84876061738     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.764409     Document Type: Review

References (102)

1. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1957;147(927):258-67
2. Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004;202:8-32
3. Thompson MR, Kaminski JJ, Kurt-Jones EA, et al. Pattern recognition receptors and the innate immune response to viral infection. Viruses 2011;3(6):920-40
4. Sadler AJ, Williams BR. Interferon-inducible antiviral effectors. Nat Rev Immunol 2008;8(7):559-68
5. David M. Interferons and microRNAs. J Interferon Cytokine Res 2010;30(11):825-8
6. Rajoriya N, Barnes E. Factors determining effectiveness of interferonsin managing hepatitis C: new targets and new approaches. Int J Interferon Cytokine Mediator Res 2010;2:85-95
7. Ashfaq UA, Javed T, Rehman S, et al. An overview of HCV molecular biology, replication and immune responses. Virol J 2011;8:161
8. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41(10):1105-9
9. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461(7265):798-801
10. Asselin-Paturel C, Trinchieri G. Production of type I interferons: plasmacytoid dendritic cells and beyond. J Exp Med 2005;202(4):461-5
11. Ortaldo JR, Herberman RB, Harvey C, et al. A species of human alpha interferon that lacks the ability to boost human natural killer activity. Proc Natl Acad Sci USA 1984;81(15):4926-9
12. Yamamoto S, Yano H, Sanou O, et al. Different antiviral activities of IFN-alpha subtypes in human liver cell lines: synergism between IFN-alpha2 and IFN-alpha8. Hepatol Res 2002;24(2):99
13. Honda K, Takaoka A, Taniguchi T. Type I interferon gene induction by the interferon regulatory factor family of transcription factors. Immunity 2006;25(3):349-60
14. Koyama T, Sakamoto N, Tanabe Y, et al. Divergent activities of interferon-alpha subtypes against intracellular hepatitis C virus replication. Hepatol Res 2006;34(1):41-9
15. Dubois A, Francois C, Descamps V, et al. Enhanced anti-HCV activity of interferon alpha 17 subtype. Virol J 2009;6:70
16. Scagnolari C, Trombetti S, Selvaggi C, et al. In vitro sensitivity of human metapneumovirus to type I interferons. Viral Immunol 2011;24(2):159-64
17. Scagnolari C, Trombetti S, Solda A, et al. Pandemic 2009 H1N1 influenza virus is resistant to the antiviral activity of several interferon alpha subtypes. J Interferon Cytokine Res 2011;31(6):475-9
18. Sheppard P, Kindsvogel W, Xu W, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003;4(1):63-8
19. Ank N, West H, Bartholdy C, et al. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 2006;80(9):4501-9
20. Sommereyns C, Paul S, Staeheli P, et al. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 2008;4(3):e1000017
21. Diegelmann J, Beigel F, Zitzmann K, et al. Comparative analysis of the lambda-interferons IL-28A and IL-29 regarding their transcriptome and their antiviral properties against hepatitis C virus. PLoS One 2010;5(12):e15200
22. Kanda T, Wu S, Kiyohara T, et al. Interleukin-29 suppresses hepatitis a and C viral internal ribosomal entry site-mediated translation. Viral Immunol 2012;25(5):379-86
23. Bach EA, Aguet M, Schreiber RD. The IFN-g receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol 1997;15:563-91
24. Schroder K, Hertzog PJ, Ravasi T, et al. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 2004;75(2):163-89
25. Witte K, Gruetz G, Volk HD, et al. Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun 2009;10(8):702-14
26. Jaitin DA, Roisman LC, Jaks E, et al. Inquiring into the differential action of interferons (IFNs): an IFN-alpha2 mutant with enhanced affinity to IFNAR1 is functionally similar to IFN-beta. Mol Cell Biol 2006;26(5):1888-97
27. Jaks E, Gavutis M, Uze G, et al. Differential receptor subunit affinities of type I interferons govern differential signal activation. J Mol Biol 2007;366(2):525-39
28. Antonelli G. Biological basis for a proper clinical application of alpha interferons. New Microbiol 2008;31(3):305-18
29. Thomas C, Moraga I, Levin D, et al. Structural linkage between ligand discrimination and receptor activation by type I interferons. Cell 2011;146(4):621-32
30. Hornung V, Latz E. Intracellular DNA recognition. Nat Rev Immunol 2010;10(2):123-30
31. Samarajiwa SA, Forster S, Auchettl K, et al. INTERFEROME: the database of interferon regulated genes. Nucleic Acids Res 2009;37(Database issue):D852-7 . Complexity of ISGs response.
32. Espert L, Degols G, Gongora C, et al. ISG20, a new interferon-induced RNase specific for single-stranded RNA, definesan alternative antiviral pathway against RNA genomic viruses. J Biol Chem 2003;278(18):16151-8
33. Fensterl V, Sen GC. The ISG56/ IFIT1 gene family. J Interferon Cytokine Res 2011;31(1):71-8
34. Kim KI, Zhang DE. ISG15, not just another ubiquitin-like protein. Biochem Biophys Res Commun 307 (3):431-4
35. Henriet S, Mercenne G, Bernacchi S, et al. Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors. Microbiol Mol Biol Rev 2009;73(2):211-32
36. Lukic Z, Campbell EM. The cell biology of TRIM5alpha. Curr HIV/AIDS Rep 2012;9(1):73-80
37. Kuhl BD, Cheng V, Wainberg MA, Liang C. Tetherin and its viral antagonists. J Neuroimmune Pharmacol 2011;6(2):188-201
38. Siegrist F, Ebeling M, Certa U. The small interferon-induced transmembrane genes and proteins. J Interferon Cytokine Res 2011;31(1):183-97
39. Seo JY, Yaneva R, Cresswell P. Viperin: a multifunctional, interferon-inducible protein that regulates virus replication. Cell Host Microbe 2011;10(6):534-9
40. Oshiumi H, Ikeda M, Matsumoto M, et al. Hepatitis C virus core protein abrogates the DDX3 function that enhances IPS-1-mediated IFN-beta induction. PLoS ONE 2010;5(12):e14258
41. Ding Q, Huang B, Lu J, et al. Hepatitis C virus NS3/4A protease blocks IL-28 production. Eur J Immunol 2012;42(9):2374-82 . Discovery of IFN-l evasion strategy employed by HCV.
42. Hofmann WP, Zeuzem S, Sarrazin C. Hepatitis C virus-related resistance mechanisms to interferon alpha-based antiviral therapy. J Clin Virol 2005;32(2):86-91
43. Abe T, Kaname Y, Hamamoto I, et al. Hepatitis C virus nonstructural protein 5A modulates the toll-like receptor-MyD88-dependent signaling pathway in macrophage cell lines. J Virol 2007;81(17):8953-66
44. Kumthip K, Chusri P, Jilg N, et al. Hepatitis C virus NS5A disrupts STAT1 phosphorylation and suppresses type I interferon signaling. J Virol 2012;86(16):8581-91
45. Kaukinen P, Sillanpaa M, Nousiainen L, et al. Hepatitis C virus NS2 protease inhibits host cell antiviral response by inhibiting IKKepsilon and TBK1 functions. J Med Virol 2013;85(1):71-82
46. Toroney R, Nallagatla SR, Boyer JA, et al. Regulation of PKR by HCV IRES RNA: importance of domain II and NS5A. J Mol Biol 2010;400(3):393-412
47. Han JQ, Barton DJ. Activation and evasion of the antiviral 2'-5' oligoadenylate synthetase/ribonuclease L pathway by hepatitis C virus mRNA. RNA 2002;8(4):512-25
48. Merup M, Tornebohm-Roche E, Engman K, et al. Human leukocyte interferon-alpha therapy can induce a second response in treatment of thrombocytosis in patients with neutralising antibodies to recombinant interferon-alpha2a. Eur J Cancer 1994;30a:1729-30
49. Musch E, Malek M, von Eick H, et al. Successful Long-term Application of Highly Purified Natural Interferon-alpha (Multiferon†) after Preceding Interferon Approaches in a ChronicHepatitis C Patient with Thrombocytopenia. Scand J Infect Dis 2004;00:1-4
50. Melian EB, Plosker GL. Interferon alfacon-1: a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C. Drugs 2001;61(11):1661-91
51. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000;343(23):1666-72
52. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395-403
53. Zeuzem S, Berg T, Moeller B, et al. Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepat 2009;16(2):75-90
54. Grace MJ, Cutler D. Pegylating IFNs at his-34 improves the in vitro antiviral activity through the JAK/STAT pathway. Antivir Chem Chemother 2004;15:287-97
55. Aghemo A, Rumi MG, Colombo M. Pegylated interferons alpha2a and alpha2b in the treatment of chronic hepatitis C. Nat Rev Gastroenterol Hepatol 2010;7:485-94
56. Singal AK, Jampana SC, Anand BS. Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naive patients with hepatitis C virus infection: meta-analysis of randomizedcontrolled trials. Dig Dis Sci 2011;56(8):2221-6
57. Alexopoulou A, Papatheodoridis GV. Current progress in the treatment of chronic hepatitis C. World J Gastroenterol 2012;18(42):6060-9
58. Moreno-Otero R, Trapero-Marugan M, Gomez-Dominguez E, et al. Is interferon-beta an alternative treatment for chronic hepatitis C? World J Gastroenterol 2006;12(17):2730-6
59. Osborn BL, Olsen HS, Nardelli B, et al. Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther 2002;303:540-8
60. Rustgi VK. Albinterferon alfa-2b, a novel fusion protein of human albumin and human interferon alfa-2b, for chronic hepatitis C. Curr Med Res Opin 2009;25:991-1002
61. De Leede LG, Humphries JE, Bechet AC, et al. Novel controlled-release Lemna-derived IFN-alpha2b (Locteron): pharmacokinetics, pharmacodynamics, and tolerability in a phase I clinical trial. J Interferon Cytokine Res 2008;28:113-22
62. Muir AJ, Shiffman ML, Zaman A, et al. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 2010;52(3):822-32
63. Konishi H, Okamoto K, Ohmori Y, et al. An orally available, small-molecule interferon inhibits viral replication. Sci Rep 2012;2:259
64. Lanford RE, Guerra B, Lee H, et al. Genomic response to interferon-alpha in chimpanzees: implications of rapid downregulation for hepatitis C kinetics. Hepatology 2006;43(5):961-72
65. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA 2008;105:7034-9
66. Barouki FM, Witter FR, Griffin DE, et al. Time course of interferon levels, antiviral state, 2',5'-oligoadenylate synthetase and side effects in healthy men. J Interferon Res 1987;7(1):29-39
67. Witter F, Barouki F, Griffin D, et al. Biologic response (antiviral) to recombinant human interferon alpha 2a as a function of dose and route of administration in healthy volunteers. 1. Clin Pharmacol Ther 1987;42:567-75
68. von Wussow P, Pralle H, Hochkeppel HK, et al. Effective natural interferon-alpha therapy in recombinant interferon-alpha-resistant patients with hairy cell leukemia. Blood 1991;78:38-43
69. Fuchs D, Norkrans G, Wejstal R, et al. Changes of serum neopterin, beta 2-microglobulin and interferon-gamma in patients with chronic hepatitis C treated with interferon-alpha 2b. Eur J Med 1992;1:196-200
70. Imam H, Janson ET, Gobl A, et al. Induction of MxA mRNA in patients with neuroendocrine tumors after interferon treatment. Lack of correlation with antitumor response. Anticancer Res 1995;15(5B):2191-5
71. Rodriguez JL, Valenzuela C, Marin N, et al. Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon alpha-2b formulations administered intramuscularly in healthy male volunteers. Biotecnologia Aplicada 2000;17:166-70
72. Motzer RJ, Rakhit A, Ginsberg M, et al. Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma. J Clin Oncol 2001;19(5):1312-19
73. Silva M, Poo J, Wagner F, et al. A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients withchronic hepatitis C (COMPARE). J Hepatol 2006;45(2):204-13
74. Bruno R, Sacchi P, Scagnolari C, et al. Pharmacodynamics of peginterferon alpha-2a and peginterferon alpha-2b in interferon-naive patients with chronic hepatitis C: a randomized, controller study. Aliment Pharmacol Ther 2007;26(3):369-76
75. Scagnolari C, Bellomi F, Trombetti S, et al. Expression of biomarkers of interferon type I in patients suffering from chronic diseases. Clin Exp Immunol 2007;147(2):270-6
76. Garcia-Garcia I, Gonzalez-Delgado CA, Valenzuela-Silva CM, et al. Pharmacokinetic and pharmacodynamic comparison of two "pegylated" interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study. BMC Pharmacol 2010;10:15
77. Scagnolari C, Zingariello P, Vecchiet J, et al. Differential expression of interferon-induced microRNAs in patients with chronic hepatitis C virus infection treated with pegylated interferon alpha. Virol J 2010;7:311
78. Giannelli G, Antonelli G, Fera G, et al. 2',5'-Oligoadenylate synthetase activity as a responsive marker during interferon therapy for chronic hepatitis C. J Interferon Res 1993;13(1):57-60
79. Antonelli G, Simeoni E, Turriziani O, et al. Correlation of interferon-induced expression of MxA mRNA in peripheral blood mononuclear cells with the response of patients with chronic active hepatitis C to IFN-alpha therapy. J Interferon Cytokine Res 1999;19(3):243-51
80. Giannelli G, Guadagnino G, Dentico P, et al. MxA and PKR expression in chronic hepatitis C. J Interferon Cytokine Res 2004;24(11):659-63
81. Chen L, Borozan I, Feld J, et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005;128(5):1437-44
82. Lau DT, Negash A, Chen J, et al. Innate immune tolerance and the role of kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection. Gastroenterology 2012;S0016-5085(12):01602
83. Abe H, Hayes CN, Ochi H, et al. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. J Hepatol 2011;54(6):1094-101
84. Honda M, Sakai A, Yamashita T, et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010;139(2):499-509
85. Shi X, Pan Y, Wang M, et al. IL28B Genetic Variation Is Associated with Spontaneous Clearance of Hepatitis C Virus, Treatment Response, Serum IL-28B Levels in Chinese Population. PLoS ONE 2012;7(5):e37054
86. Naggie S, Osinusi A, Katsounas A, et al. Dysregulation of innate immunity in hepatitis C virus genotype 1 IL28B-unfavorable genotype patients: impaired viral kinetics and therapeutic response. Hepatology 2012;56(2):444-54
87. Younossi ZM, Birerdinc A, Estep M, et al. The impact of IL28B genotype on the gene expression profile of patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin. J Transl Med 2012;10:25
88. Li W, Jiang Y, Jin Q, et al. Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population. 2011;31(8):1118-26
89. Dill MT, Duong FH, Vogt JE, et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 2011;140:1021-31
90. Urban TJ, Thompson AJ, Bradrick SS, et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010;52(6):1888-96
91. Kong XF, Zhang XX, Gong QM, et al. MxA induction may predict sustained virologic responses of chronic hepatitis B patients with IFN-alpha treatment. J Interferon Cytokine Res 2007;27(9):809-18
92. El Awady MK, Anany MA, Esmat G, et al. Single nucleotide polymorphism at exon 7 splice acceptor site of OAS1 gene determines response of hepatitis C virus patients to interferon therapy. J Gastroenterol Hepatol 2011;26(5):843-50
93. Ren S, Yu H, Zhang H, et al. Polymorphisms of interferon-inducible genes OAS associated with interferon-alpha treatment response in chronic HBV infection. Antiviral Res 2011;89(3):232-7
94. Stevenson NJ, Murphy AG, Bourke NM, et al. Ribavirin enhances IFN-alpha signalling and MxA expression: a novel immune modulation mechanism during treatment of HCV. PLoS One 2011;6(11):e27866
95. Antonelli G. In vivo development of antibody to interferons: an update. J Interferon Cytokine Res 1997;17:S39-46
96. Strayer DR, Carter WA. Recombinant and natural human interferons: analysis of the incidence and clinical impact of neutralizing antibodies. J Interferon Cytokine Res 2012;32(3):95-102
97. Scagnolari C, Casato M, Bellomi F, et al. Serum interferon (IFN)-neutralizing antibodies and bioactivities of IFNs in patients with severe type II essential mixed cryoglobulinemia. Clin Diagn Lab Immunol 2003;10(1):70-7
98. Antonelli G, Dianzani F. Development of antibodies to interferon beta in patients: technical and biological aspects. Eur Cytokine Netw 1999;10(3):413-22
99. van der Eijk AA, Vrolijk JM, Haagmans BL. Antibodies neutralizing peginterferon alfa during retreatment of hepatitis C. N Engl J Med 2006;354(12):1323-4
100. Santantonio T, Milella M, Antonelli G, et al. Neutralizing antibodies to interferon alpha in a chronic hepatitis C patient non-responder to pegylated interferon. J Hepatol 2006;45(5):759-61
101. Scagnolari C, Trombetti S, Solda A, et al. Development and specificities of anti-interferon neutralizing antibodies in patients with chronic hepatitis C treated with pegylated interferon-alpha. Clin Microbiol Infect 2011
102. Nolte KU, Gunther G, von Wussow P. Epitopes recognized by neutralizing therapy-induced human anti-interferon-alpha antibodies are localized within the N-terminal functional domain of recombinant interferon-alpha 2. Eur J Immunol 1996;26:2155-9